Literature DB >> 7139124

An alternative extrinsic pathway of human blood coagulation.

R A Marlar, A J Kleiss, J H Griffin.   

Abstract

To study the interrelationships of the major human coagulation pathways, factor X activation in normal and various deficient human plasmas was evaluated when clotting was triggered by dilute rabbit or human thromboplastin. Various dilutions of thromboplastin were added to plasma samples containing 3H-labeled factor X, and the time course of factor X activation was determined. At a 1/250 dilution of rabbit brain thromboplastin the rate of factor X activation in factor VIII or factor IX deficient plasma was only 10% of the activation rate seen for normal or factor XI deficient plasma. Reconstitution of the deficient plasmas with factors VIII or IX, respectively, restored normal factor X activation. Similar results were obtained when various dilutions of human thromboplastin replaced the rabbit thromboplastin. From these experiments, it is inferred that normal activation of factor X in plasma due to dilute thromboplastin requires factors VII, IX and VIII. An alternative extrinsic pathway that involves factors VII, IX, and VIII may be a major physiologic extrinsic pathway, and this pathway may help to explain the clinical observations of bleeding diatheses in patients deficient in factors IX or VIII.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins.

Authors:  S G Spitzer; B J Warn-Cramer; C K Kasper; S P Bajaj
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

2.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.

Authors:  K M Brinkhous; U Hedner; J B Garris; V Diness; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.

Authors:  T A Drake; J H Morrissey; T S Edgington
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

4.  Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.

Authors:  D Repke; C H Gemmell; A Guha; V T Turitto; G J Broze; Y Nemerson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects.

Authors:  H J Weiss; V T Turitto; H R Baumgartner
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

6.  Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.

Authors:  C R Benedict; J Ryan; B Wolitzky; R Ramos; M Gerlach; P Tijburg; D Stern
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 7.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

8.  Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite.

Authors:  Yang Buyue; John P Sheehan
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.